叮噹健康旗下藥房上架百濟神州注射用澤尼達妥單抗(百赫安)
日前, 百濟神州雙特異性HER2抑制劑百赫安(注射用澤尼達妥單抗)首批藥物在叮噹健康旗下藥房等渠道上架發售,6 月24日,於叮噹健康旗下藥房正式售出首單。

資料顯示,百濟神州有限公司是一家全球腫瘤治療創新公司。注射用澤尼達妥單抗於2025年5月29日,獲附條件批準,用於既往接受過治療的患者。
叮噹健康相關負責人表示:"新特藥是叮噹健康十分重視的領域,一直以來,公司圍繞腫瘤、自免、神經系統等疾病領域持續擴充品類。本次上架百赫安,旨在爲中國晚期膽道癌提供新的用藥選擇以及更多希望"。
據瞭解,叮噹健康於2025年持續推進新特藥‘生命方舟計劃’,在旗下藥房全面加強新特藥品類佈局,已先後上架阿爾茨海默病藥品記能達、1類新藥注射用瑞康曲妥珠單抗(艾維達)等新特藥產品,爲提升患者用藥可及性帶來便利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.